A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.

CONCLUSION: Non-inferiority of dTap-IPVB to dTap-IPVR was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3-4 years old. TRIAL REGISTRATION: NCT01245049 (ClinicalTrials.gov). PMID: 29576304 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29576304?dopt=Abstract

Source: Vaccine - March 22, 2018 Category: Allergy & Immunology Authors: Marlow R, Kuriyakose S, Mesaros N, Han HH, Tomlinson R, Faust SN, Snape MD, Pollard AJ, Finn A Tags: Vaccine Source Type: research